Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Niagen Bioscience, Inc. - Common Stock (NQ:NAGE)

2.700 -0.220 (-7.53%)
Delayed Quote Updated: 3:34 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,067,093
Open 2.910
Bid (Size) 2.700 (1,400)
Ask (Size) 2.710 (2,000)
Prev. Close 2.920
Today's Range 2.670 - 2.920
52wk Range 2.870 - 9.915
Shares Outstanding 68,196,526
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®” a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
From Niagen Bioscience, Inc
Via Business Wire

Performance

YTD
-56.8%
-56.8%
1 Month
-13.7%
-13.7%
3 Month
-18.9%
-18.9%
6 Month
-40.3%
-40.3%
1 Year
-71.1%
-71.1%

More News

Read More
News headline image
Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes
From Niagen Bioscience, Inc.
Via Business Wire
Niagen Bioscience (NASDAQ:NAGE) Shares Slide After Q1 Earnings Miss and Spending Guidance ↗
Via Chartmill
Topics Earnings
News headline image
Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Present at Canaccord Genuity’s Well Summit
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Present at Longevity Investors Conference
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
From Niagen Bioscience, Inc.
Via Business Wire
News headline image
Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
From Niagen Bioscience, Inc.
Via Business Wire
News headline image
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
From Niagen Bioscience, Inc.
Via Business Wire
News headline image
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen (NAGE) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
From Niagen Bioscience, Inc
Via Business Wire

Frequently Asked Questions

Is Niagen Bioscience, Inc. - Common Stock publicly traded?
Yes, Niagen Bioscience, Inc. - Common Stock is publicly traded.
What exchange does Niagen Bioscience, Inc. - Common Stock trade on?
Niagen Bioscience, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Niagen Bioscience, Inc. - Common Stock?
The ticker symbol for Niagen Bioscience, Inc. - Common Stock is NAGE on the Nasdaq Stock Market
What is the current price of Niagen Bioscience, Inc. - Common Stock?
The current price of Niagen Bioscience, Inc. - Common Stock is 2.700
When was Niagen Bioscience, Inc. - Common Stock last traded?
The last trade of Niagen Bioscience, Inc. - Common Stock was at 10/01/26 03:34 PM ET
What is the market capitalization of Niagen Bioscience, Inc. - Common Stock?
The market capitalization of Niagen Bioscience, Inc. - Common Stock is 184.14M
How many shares of Niagen Bioscience, Inc. - Common Stock are outstanding?
Niagen Bioscience, Inc. - Common Stock has 184M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.